Motif Bio Share Discussion Threads

[timw3] 04/10/2017 13:37

Current price is around $10 US, $32 US is 3 times this :)

Motif Bio price target raised to $32 from $25 at H.C. Wainwright H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Motif Bio to $32 saying the Revice-2 Phase 3 trial hit the endpoints "with flying colors." The data position iclaprim favorably for FDA approval, Selvaraju tells investors in a research note. He keeps a Buy rating on the shares.

Read more at:
hxxps://thefly.com/landingPageNews.php?id=2618157

[timw3] 04/10/2017 13:27

David:"Published literature showing Icaloprim works twice as fast as Vancomycin"

[return_of_the_apeman] 04/10/2017 13:24

Anyone listening to the call? I am on the golf course (well more in the bushes)

[timw3] 04/10/2017 13:23

"Fulford group is seeking commercialisation partners...The results from today will enhance this process considerably."

[btfd] 04/10/2017 13:10

there'll be a buy out here. Pharma giants have cash to burn on successful phase 3's.. never mind in anti biotics

[babbler] 04/10/2017 12:52

9 mins to call time...

[miahkaysor] 04/10/2017 12:37

It is envisaged share price will spike sharply when NASDAQ opens this afternoon!!!!

[saw89] 04/10/2017 12:37

Loaded up more - only going one way . Bargain at these prices.

[gersemi] 04/10/2017 12:08

just bought another 15000

[miahkaysor] 04/10/2017 12:02

im topping up!!!!

clearly 70p next few days!!

[pyglet] 04/10/2017 11:40

top up time!!

[saw89] 04/10/2017 11:15

Liking the rise so far looks like good liquitidy here not a huge suffle spike should rise nicely for days and weeks to come.

[ohisay] 04/10/2017 11:11

hxxps://labiotech.eu/antibiotic-resistance-motif-bio/

[waterloo01] 04/10/2017 11:08

Cheers again.

[saw89] 04/10/2017 11:07

Good idea to keep loading up before NASDAQ opens..

[drmaccers] 04/10/2017 11:06

1 phase 3 trail away from using it in hospital acquired bacterial pneumonia and have orphan status for Cystic Fibrosis. Both of those are potentially bigger again

[ohisay] 04/10/2017 11:05

hxxp://ir.motifbio.com/phoenix.zhtml?c=254416&p=irol-EventDetails&EventId=5264065

webcast this pm

[waterloo01] 04/10/2017 11:03

Cheers. I know vanco is cheap but good to hear they have done marketing studies and have solid indications that Dr's as well as payers (US insurance) seem keen. Mention of wider uses but not sure where they are with that.

[ctrlseng] 04/10/2017 11:02

10:56 - 04/10 Sell 669363 45.00p £301,213.35

08:23 - 04/10 Sell 500000 46.75p £233,750.00


Was that really a SELL? Why would someone be selling today for this price?

[drmaccers] 04/10/2017 11:01

Need 400% from here to get to parity with paratek

[drmaccers] 04/10/2017 11:01

WaterlooAround $3500 a course

[gersemi] 04/10/2017 10:58

thanks to Ian.B from LSE: A licencing deal, maybe

Ian.B
Posts: 14,146
Off Topic
Opinion: No Opinion
Price: 51.75
Fincap sqwark
Today 10:54
I mentioned potential for ROW licencing deals before q1 2018 FDA submissions in an earlier post..

Fincapp
Motif Bio (BUY)
Iclaprim passes pivotal Phase 3 trial
Motif Bio (MTFB) has announced positive top-line results from its REVIVE-2 study that shows clinical equivalence to vancomycin when used to treat acute bacterial skin & skin infections (ABSSSI). In the REVIVE-2 study, iclaprim met its primary endpoints (78.8% vs 76.7% for vancomycin) for an early clinical response with minimal side effects that were all recorded as mild. Iclaprim also achieved non inferiority to vancomycin at the test of cure endpoint (7-14 days) after the end of treatment. MTFB expects to file NDA submission in Q1-18, with it possible that a partnering/licence deal is forthcoming on the back of these pivotal positive Phase III results. We retain our 100p price target and Buy recommendation pending FDA formal approval in 2018.

[timw3] 04/10/2017 10:44

Nasdaq news release

[fission453] 04/10/2017 10:39

Twitter going mental!

They reckon these should be £1.50 right now!!!!!